At Polpharma Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals, our international management team brings both knowledge and passion to every project.
Jerzy Starak, Chairman of the Supervisory Board of Polpharma Biologics S.A, belongs to the group of Polish entrepreneurs, whose activities contributed to the modernization of the Polish economy. Visionary, who does not lack the courage, determination and perseverance in making difficult business challenges. Thanks to his activity, companies such as Baxter, Bols, Lessafre, Sanofi, Bunge, Nutricia and Colgate-Palmolive, appeared in Poland. In 2000, became the owner of Polpharma S.A. in Starogard Gdanski, joined by Medana Pharma S.A. Sieradz Branch Duchnice purchased from the company Bioton Warsaw Polfa S.A. and the company Sanfarm, transformed into a branch of Production in Nowa Deba.
Hannes Teissl is a seasoned biopharmaceutical executive with a track record in general management, business turnaround, finance, business development and M&A. Hannes is a Supervisory Board Member of Polpharma Biologics S.A., a company which he was instrumental in establishing over the last 7 years. Prior to joining Polpharma Biologics, Hannes served 22 years at Sandoz, where he held various international management positions, such as Member of the Global Executive Committee, Global Head of M&A, CEO of Sandoz Germany, Global Head of Biopharmaceuticals, Global Commercial Head of API & Out-Licensing for an Anti-infectives and CEO of Sandoz Germany. Hannes holds a Master of Economics from the University of Innsbruck.
Dr Joerg Windisch
President of the Management Board
Dr. Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. Since joining Polpharma Biologics, Dr. Windisch has made significant contributions to the organization’s formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr. Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr. Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as Chief Scientific Officer (CSO) for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.
Member of the Management Board
Jan Krzewinski is a Management Board Member and CFO of Polpharma Biologics. Prior to his current position Jan held various roles at Polpharma including the Director of the Chariman’s Strategic Projects Office. Before joining Polpharma he spent almost 9 years working for Mid Europa Partners, the largest CEE-focused private equity fund where he was responsible for executing and monitoring investments. While at Mid Europa Partners Jan held supervisory board-level positions at Lux Med, Diagnostyka, Alpha Medical and Polskie Koleje Linowe. Jan continues to serve on the supervisory boards of Herbapol Lublin and the EFC Educational Foundation. Jan is a graduate of the London School of Economics and Political Science (BSc) and Johns Hopkins University, SAIS (MA).
Dr Nicholas Hunt
Director Technical Research
Dr. Nicholas Hunt has more than 25 years of experience in the Biotech/Pharma sector and after having received his BSc in Microbiology and Virology and a PhD in Molecular Virology both from the University of Warwick, UK he has worked in and managed a number of different R&D organizations in a variety of companies in a number of countries. His experience includes leading large multi interdisciplinary R&D groups in developing novel and Biosimilar medicines as well as multi-site CMO GMP manufacturing companies such as Richter-Helm-Biologics. He has spent the last six years at Alvotech in Iceland where from the very beginning of this venture he was instrumental in building up the CMC target portfolio and GMP manufacturing competencies as well as state of the art single use mammalian manufacturing facility. During this period he also taught Biotechnology at the University of Iceland.
Dr Adriana Kiędzierska-Mencfeld
Technical Operations Director
Dr. Kiędzierska-Mencfeld has more than 10 years of experience in recombinant protein purification and expression in both prokaryotic and eukaryotic systems, and six years of experience in the development and GMP production of biosimilars. Prior to joining Polpharma Biologics as Production Director, Dr. Kiedzierska-Mencfeld spent four years as Head of GMP Production at the biotechnology firm Mabion S.A. She earned her Ph.D. in biochemistry from the Institute of Biochemistry and Molecular Biology at the University of Wroclaw, her MS in molecular biotechnology and biocatalysis from the Technical University of Wroclaw, and completed her master’s thesis at the Technical University of Dresden.
Marlena Nowak has more than 23 years of experience in the pharmaceutical industry. She started at Polpharma as a QC Specialist, and she continued in the same role for a further next 4 years as a QA Specialist. Then she moved to GSK to work in the QA operationsal area. In 2005, again Marlena came back to work for Polpharma in Starogard Gdański, to lead the QA operations team. Prior to joining Polpharma Biologics as Quality Director, Marlena spent 4 years as Quality Assurance Manager and 5 years as Site Quality Head, leading 2 sites in Poland, at Novartis. She has an MSc in chemistry from Gdańsk University. Marlena is a board member of the Polish ISPE Polish Affiliate.
Lidia Ołowska is HR professional with more than 20 years of international experience in pharmaceutical sector, global organizations and matrix setups. Prior to joining Polpharma Biologics Lidia has served as HR & Communication Director for Novo Nordisk A/S in Poland, Russia and Italy being responsible for setting and execution of HR strategy in more than 25 countries of Europe and Asia as well as start-up of the first greenfield, modern insulin production facility in Russia. She is focused on contributing to the business by ensuring organization excellence, enhancing leadership and developing solutions for the business objectives delivery. Lidia is a graduate of Oxford Brookes University (MBA), has completed post-graduate studies in Coaching at SWPS University of Social Sciences and Humanities and HR Strategies at Warsaw School of Economics.
& Business Development
Tomasz Góralczyk has more than 17 years of experience in pharmaceutical business development, including both licensing-in and licensing-out. Tomasz started at Polpharma as New Product Acquisition Manager, identifying and initiating opportunities to expand the organization’s portfolio of products. He then led the formation of Polpharma’s out-licensing department and strategy as Licensing-Out Director, where he was responsible for licensing out products developed by the Polpharma group of companies. Prior to his time at Polpharma, Tomasz was Head of the Foreign Projects Department at Adamed. He has an MSc in molecular biology from Jagiellonian University in Kraków.
Strategy & PMO
Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management and launch with a focus in oncology. She has over 16 years experience in pharmaceuticals, 8 years originators, 6 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees. Previously Alex was an Associate Principal at McKinsey, a Director for Business Development at MorphoSys and was responsible for bringing rituximab biosimilar to market in the EU, Japan, Australia, and Switzerland with Sandoz. Most recently she headed strategy and Novartis collaborations for Sandoz. She currently heads strategy and portfolio for Polpharma Biologics.
Dr Karsten Roth
Director Clinical Research & Development
Dr Karsten Roth leads the clinical development activities at Polpharma Biologics. Before joining Polpharma Biologics, Karsten worked at Mundipharma Biologics (formerly Cinfa Biotech) where he served as Director Clinical Operations & Pharmacovigilance. In his 5-year tenure there, Karsten was instrumental in designing and execution of the development and achieving EMA approval for Pelmeg®, a pegfilgrastim biosimilar. Before that, Karsten spent 8 years at Sandoz Biopharmaceuticals, serving, among other roles, as Head Clinical Development Immunology and Head Clinical Development Hematology. He substantially contributed to several Biosimilar marketing authorization submissions for the US and EU which are on the market globally today. He presented at FDA, PMDA and EMA meetings, and was setting up and leading global advisory boards for various products. Prior to joining Sandoz, Karsten worked at Astellas, Novartis Pharma and Quintiles, in clinical R&D. Overall, Karsten has 24 years of experience in this area. Karsten holds a PhD in biochemistry, a postgraduate degree in pharmaceutical medicine and a master’s in project management from the George Washington University. Karsten is also a Vice Chair of Biosimilars Medicines Group, a sector of Medicines for Europe.
Director Operational Excellence
Simon Adams joined Polpharma Biologics from Gedeon Richter where he was instrumental in building up the Debrecen biotechnology site. Prior to joining Gedeon Richter he was the operational readiness leader at Biogen’s new greenfield site in Luterbach, Switzerland, working to ensure a smooth startup and actively managing risks at all levels. Before that, Simon worked, among others, at Pall, CMC Biologics (now AGC Biologics), Lonza Biologics, Novartis and GlaxoSmithKline. He holds an honors degree from the University of Greenwich in the UK and served in the Royal Naval Reserve during his university years.
Jonathan RF Robinson is the CEO of Bioceros, he was appointed to the position in January 2020. Jonathan has 28 years experience in the Pharma and Biotech sectors. He started his career as a Scientific Officer in NHS Pathology, after 4 years he retrained as a Process Engineer and started his first engineering assignment at ICI bioproducts in Billingham UK. He has moved through various leadership roles in facility start up and production management of both small and large molecule manufacturing sites at Searle, Chirex, and Avecia Billingham (now Fujifilm). For the past 14 years he has been working in Business development. His first major role was at CPI (UK) where he helped to secure the funding for the development of the National Biologics Manufacturing Centre (Darlington) and built the client pipeline which secured its future. Prior to joining Bioceros, Jonathan was VP Business development for Abzena, where he was successful in securing business for this UK/US based Biologics CDMO. Jonathan has a HND in Medical Laboratory Sciences (Birmingham), a BSc Hons in Process Biotechnology (Teesside) and an MBA (Durham).
Dr Louis Boon
Chief Scientific Officer, Bioceros
Dr. Louis Boon is Chief Scientific Officer and Managing Director for Bioceros, a division of Polpharma Group. He is experienced in molecular and cellular immunology and therapeutic antibody development, and has been involved in the trajectory of preclinical preparation and design of first-into-man studies using therapeutic antibodies. A founder of Bioceros BV, Dr. Boon has held various scientific management roles throughout his career, including CSO for 4AZA Bioscience NV and Director of Preclinical R&D for MacroZyme BV. After completing his post-doctoral studies, Dr. Boon helped to found PanGenetics, where he would later hold the position of VP Preclinical (ad interim) following the company’s merger with Tanox Inc. He received his Ph.D. in biochemistry from the University of Amsterdam and completed his post-doctoral work at the University of Amsterdam’s Department of Anatomy and Embryology and Department of Clinical Epidemiology.
Mission and Vision
We aim to develop high-quality biologic medicines to treat a wide range of conditions and to make these therapies accessible to those who need them.
Employee Attitudes & Behaviors
We adhere to a set of guiding principles meant to foster a positive, enriching atmosphere for our staff and deliver value to all of our stakeholders.